Via practica 1/2005
DIABETIC DYSLIPIDAEMIA – IMPORTANT PART OF THE COMPLEX CARE FOR THE PATIENTS WITH DIABETES TYPE 2
It is now well estalished that cardiovascular risk is extremely high in patients with diabetes type 2. The benefits of lipid modification (reduction of LDL-cholesterol and triglycerides and increasing of HDL-cholesterol) in this patient group are clear from emerging data from clinical trials. Since the publication of NCEP ATP III in 2001 new clinical trials with clinical end points have been published. Results of these trials are reflected in the recent update, which now recommend new targets for patients with diabetes type 2.
Keywords: diabetic dyslipidemia, prevention, target levels.
